INTRODUCTION
SAD
GRAM-POSITIVE BACTERIAL INFECTIONS
The emergence of multidrug-resistant Gram-positive bacteria, including methicillin-resistant Contezolid (also known as MRX-I) is a fully synthetic oxazolidinone antimicrobial agent, independently developed by Shanghai MicuRx Pharmaceutical Inc (MicuRx). It was approved for treating multidrug-resistant Gram-positive bacterial infections in China in 2021 (In order to bridge with the data in the US and facilitate the approval of contezolid acefosamil in China and other countries simultaneously, a phase I clinical trial was conducted in healthy Chinese subjects. This placebo-controlled phase I study aimed to evaluate the safety, tolerability, and PK characteristics of contezolid and related metabolites after intravenous and oral administration of single ascending dose (SAD) and multiple doses of contezolid acefosamil in healthy Chinese subjects.